VEGF-121 plasma level as biomarker for response to anti-angiogenetic therapy in recurrent glioblastoma

BACKGROUND: Vascular endothelial growth factor (VEGF) isoforms, particularly the diffusible VEGF-121, could play a major role in the response of recurrent glioblastoma (GB) to anti-angiogenetic treatment with bevacizumab. We hypothesized that circulating VEGF-121 may reduce the amount of bevacizumab...

Descripción completa

Detalles Bibliográficos
Autores principales: Martini, Maurizio, de Pascalis, Ivana, D’Alessandris, Quintino Giorgio, Fiorentino, Vincenzo, Pierconti, Francesco, Marei, Hany El-Sayed, Ricci-Vitiani, Lucia, Pallini, Roberto, Larocca, Luigi Maria
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946426/
https://www.ncbi.nlm.nih.gov/pubmed/29747600
http://dx.doi.org/10.1186/s12885-018-4442-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5946426/
https://www.ncbi.nlm.nih.gov/pubmed/29747600
http://dx.doi.org/10.1186/s12885-018-4442-2

Ejemplares similares